Larry Allen, MD, MHS, College of Colorado Anschutz Medical Campus.
Scott Lundgren, DO, Nebraska Medication.
FDA: “What You Must Know (And What We’re Working to Discover Out) About Merchandise Containing Hashish or Hashish-derived Compounds, Together with CBD,” “FDA Approves First Drug Comprised of an Energetic Ingredient Derived from Marijuana to Deal with Uncommon, Extreme Types of Epilepsy,” “FDA and Hashish: Analysis and Drug Approval Course of.”
JCI Perception: “A single dose of cannabidiol reduces blood strain in wholesome volunteers in a randomized crossover research.”
Oxidative Medication and Mobile Longevity: “Therapeutic Purposes of Cannabinoids in Cardiomyopathy and Coronary heart Failure.”
Hashish and Cannabinoid Analysis: “An Replace on Security and Aspect Results of Cannabidiol: A Assessment of Scientific Knowledge and Related Animal Research.”
ClinicalTrials.gov: “Cannabidiol in Sufferers With Coronary heart Failure in AHA/ACC Phases A-C (CAPITAL-AC).” NCT03634189.
Journal of Cardiac Failure: “Marijuana Use is Related to Higher Hospital Final result in Sufferers with Acute Coronary heart Failure: A Propensity Match Evaluation from Nationwide Inpatient Database.”